Scarica l'app Stockscreener
4.23
3.86%
-0.17
Dopo l'orario di chiusura:
4.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.40
Aprire:
$4.7
Volume 24 ore:
470.85K
Relative Volume:
1.34
Capitalizzazione di mercato:
$302.49M
Reddito:
-
Utile/perdita netta:
$-72.89M
Rapporto P/E:
-1.7479
EPS:
-2.42
Flusso di cassa netto:
$-68.47M
1 W Prestazione:
-21.08%
1M Prestazione:
+3.68%
6M Prestazione:
-64.21%
1 anno Prestazione:
-58.41%
Intervallo 1D:
$4.125
$4.70
Intervallo di 1 settimana:
$4.125
$5.36
Portata 52W:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Nome
Astria Therapeutics Inc
Settore
Industria
Telefono
617-349-1971
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta ATXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
4.23 | 302.49M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-29 | Iniziato | TD Cowen | Buy |
| 2023-03-28 | Iniziato | Evercore ISI | Outperform |
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
Wells Fargo & Company MN Acquires 7,563 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Is Astria Therapeutics, Inc. (ATXS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Astria Therapeutics Inc (ATXS)’s Day in Review: Closing at 4.42, Up by 1.14 - DWinneX
Transcript : Astria Therapeutics, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 10 - marketscreener.com
Astria Therapeutics at Citizens JMP: Advancing HAE Treatments By Investing.com - Investing.com India
Astria Therapeutics at Citizens JMP: Advancing HAE Treatments - Investing.com Australia
Raymond James Financial Inc. Buys Shares of 79,044 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Barclays PLC Boosts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Long Term Investment Analysis - news.stocktradersdaily.com
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $161,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Astria Therapeutics Inc (ATXS) - Sete News
Financial Metrics Check: Astria Therapeutics Inc (ATXS)’s Ratios for Trailing Twelve Months - DWinneX
Brokers Set Expectations for ATXS FY2025 Earnings - Defense World
Breaking down ATXS’s current quarter earnings estimates - uspostnews.com
Astria Therapeutics Announces Publication of Navenibart Phase 1a - GuruFocus
Astria Therapeutics reports progress in HAE drug trial By Investing.com - Investing.com India
Astria Therapeutics reports progress in HAE drug trial - Investing.com
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Holdings Increased by Legal & General Group Plc - Defense World
Astria Therapeutics (ATXS) to Release Quarterly Earnings on Thursday - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Position Increased by JPMorgan Chase & Co. - Defense World
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference | ATXS Stock News - GuruFocus
Cantor Fitzgerald Upgrades Astria Therapeutics (NASDAQ:ATXS) to “Strong-Buy” - Defense World
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference - Business Wire
Astria Therapeutics (ATXS) Receives Overweight Rating with Promi - GuruFocus
Cantor Fitzgerald Initiates Coverage of Astria Therapeutics (ATXS) with Overweight Recommendation - Nasdaq
Astria Therapeutics (ATXS) Receives Overweight Rating with Promising Prospects | ATXS Stock News - GuruFocus
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $26.60 Consensus Price Target from Analysts - Defense World
Ratios Revealed: Decoding Astria Therapeutics Inc (ATXS)’s Financial Health - DWinneX
Astria Therapeutics Inc (ATXS) stock analysis: A simple moving average approach - uspostnews.com
Geode Capital Management LLC Sells 2,770 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
ATXS’s Stock Dilemma: Astria Therapeutics Inc’s Market Performance and Outlook - investchronicle.com
Top Premarket Decliners - marketscreener.com
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Vanguard Group Inc. - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Raymond James Financial Inc. Takes $707,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Long Term Trading Analysis for (ATXS) - news.stocktradersdaily.com
Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Grants $235K Worth of Stock Options to Strategic New Hires - Stock Titan
Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $26.60 - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Swiss National Bank - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by Swiss National Bank - The AM Reporter
Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Investment Report - news.stocktradersdaily.com
Astria Therapeutics Inc Azioni (ATXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):